左卡尼汀联合重组人促红素治疗肾性贫血患者的效果  

Effects of Levocarnitine combined with recombinant human erythropoietin in treatment of patients with renal anemia

作　　者：尹伟洲 YIN Weizhou(Department of Nephrology of the First Affiliated Hospital of Nanyang Medical College,Nanyang 473000 Henan,China)

机构地区：[1]南阳医学高等专科学校第一附属医院肾内科,河南南阳473000

出　　处：《中国民康医学》2025年第5期50-53,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察左卡尼汀联合重组人促红素治疗肾性贫血患者的效果。方法:选取2020年3月至2023年12月该院收治的86例肾性贫血患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各43例。两组均进行常规治疗,在此基础上,对照组予以重组人促红素治疗,研究组在对照组基础上联合左卡尼汀治疗,两组均治疗3个月。比较两组临床疗效,治疗前后铁代谢指标[血清铁蛋白(SF)、转铁蛋白饱和度(TS)]、炎性指标[白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]、肾功能指标[血肌酐(Scr)、血尿素氮(BUN)]水平,以及不良反应发生率。结果:研究组治疗总有效率为90.70%(39/43),高于对照组的74.42%(32/43),差异有统计学意义(P<0.05);治疗后,两组SF、TS水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组IL-6、CRP、TNF-α水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组Scr、BUN水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:左卡尼汀联合重组人促红素治疗肾性贫血患者可提高治疗总有效率,改善铁代谢指标水平,降低炎性指标、肾功能指标水平,效果优于单纯重组人促红素治疗。Objective:To observe effect of Levocarnitine combined with recombinant human erythropoietin in treatment of patients with renal anemia.Methods:A prospective study was conducted on 86 patients with renal anemia admitted to the hospital from March 2020 to December 2023.According to the random number table method,they were divided into control group and study group,43 cases in each group.Both groups received routine treatment.On this basis,the control group was treated with recombinant human erythropoietin,while the study group was treated with Levocarnitine on the basis of that of the control group.Both groups were treated for 3 months.The clinical efficacy,the levels of iron metabolism indexes [serum ferritin(SF),transferrin saturation(TS)],inflammatory indexes [interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)] and renal function indexes [serum creatinine(Scr),blood urea nitrogen(BUN)] before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 90.70%(39/43),which was higher than 74.42%(32/43) of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of SF and TS in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IL-6,CRP and TNF-α in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of Scr and BUN in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusi

关 键 词：左卡尼汀 重组人促红素 肾性贫血 铁代谢 炎性指标 肾功能 不良反应 

分 类 号：R556[医药卫生—血液循环系统疾病]